Immunovant Inc
NASDAQ:IMVT

Watchlist Manager
Immunovant Inc Logo
Immunovant Inc
NASDAQ:IMVT
Watchlist
Price: 26.01 USD -0.65% Market Closed
Market Cap: $4.6B

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
Immunovant Inc
NASDAQ:IMVT
4.5B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Immunovant Inc
Glance View

Market Cap
4.6B USD
Industry
Biotechnology

Immunovant Inc. stands as a notable player in the biopharmaceutical industry, on a mission to develop innovative treatments for autoimmune diseases. Founded with an aim to transform the lives of patients, the company is centered around harnessing the power of monoclonal antibodies to address significant unmet medical needs. At the heart of its research and development lies a pivotal asset: a novel, fully human monoclonal antibody known as IMVT-1401. This compound targets the neonatal Fc receptor (FcRn) and has shown promise in modulating the body's immune responses, which could potentially offer relief to those suffering from debilitating autoimmune conditions. By engaging in advanced clinical trials, Immunovant aims to validate the efficacy and safety of its treatments, and bring them successfully through regulatory approvals—a process that underpins the core of its operations. Immunovant monetizes its groundbreaking research through strategic partnerships, funding initiatives, and ultimately, the commercialization of its developed therapeutics. The company’s progress is closely watched by investors and analysts who are keen on its ability to navigate the complex paths of drug development and approval. Generating revenue depends heavily on reaching key developmental milestones, gaining marketing approval, and securing licenses or collaborations with larger pharmaceutical companies—a common pathway in the biopharma sector. These ventures reflect Immunovant’s strategy to build a competitive edge through cutting-edge science and strategic alliances, thus working towards the broader goal of addressing critical health challenges and achieving financial sustainability.

IMVT Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top